Drug Profile
Research programme: activin receptor type IIb fusion proteins - Atara Biotherapeutics
Alternative Names: Activin II antagonists - Atara; ActR2B antagonists - AtaraLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen
- Developer Atara Biotherapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Myostatin inhibitors; Type-II-B activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 01 Sep 2012 Atara Biotherapeutics in-licenses ActRIIB5 from Amgen (Atara Biotherapeutics 10-K, February 2015)
- 01 Sep 2012 Early research in Undefined indication in USA (unspecified route)